Page 211 - Drug Class Review
P. 211
Drug Effectiveness Review Project
Authors and Year: Tariot et al. 2000; Cummings et al. 2004; Galasko et al., 2004
galantamine placebo 8; 16; 24 mg/d 72.0% 75.5%; 73.8%; 80.2% 4.5% 5.7%; 13.3%; 16.5% 9.4% 15%;10%; 8.1% 5.9% 5%; 12%; 5.5% Post randomization exclusions: NR Overall loss to follow-up: 20.7% Loss to follow-up differential high: Yes placebo galantamine 8; 16; 24 mg/d 16% 22.8%; 21.5%; 22.3% 6.9% 6.4%; 6%; 9.8% Page 136 of 205
NR ITT: Yes Yes Yes Yes Fair
Final Report Update 1 ADVERSE EVENTS: Overall adverse effects reported: Nausea • Agitation • Diarrhea • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs
